Positron Lymphography via Intracervical
Adult
Aged
Aged, 80 and over
Cervix Uteri
Endometrial Neoplasms
/ diagnostic imaging
False Positive Reactions
Female
Fluorodeoxyglucose F18
/ administration & dosage
Humans
Imaging, Three-Dimensional
Injections
Lymphography
Middle Aged
Positron Emission Tomography Computed Tomography
Preoperative Period
Sentinel Lymph Node Biopsy
/ methods
Uterine Cervical Neoplasms
/ diagnostic imaging
PET
cervical cancer
metastasis
positron lymphography
sentinel lymph node
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
02
05
2019
accepted:
11
12
2019
pubmed:
12
1
2020
medline:
30
12
2020
entrez:
12
1
2020
Statut:
ppublish
Résumé
The presence of metastasis in local lymph nodes (LNs) is a key factor influencing choice of therapy and prognosis in cervical and endometrial cancers; therefore, the exploration of sentinel LNs (SLNs) is highly important. Currently, however, SLN mapping requires LN biopsy for pathologic evaluation, since there are no clinical imaging approaches that can identify tumor-positive LNs in early stages. Staging lymphadenectomy poses risks, such as leg lymphedema or lymphocyst formation. Furthermore, in 80%-90% of patients, the explored LNs are ultimately tumor-free, meaning most patients are unnecessarily subjected to lymphadenectomy.
Identifiants
pubmed: 31924717
pii: jnumed.119.230714
doi: 10.2967/jnumed.119.230714
pmc: PMC7413230
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1123-1130Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Ann Surg Oncol. 2017 Aug;24(8):2174-2181
pubmed: 28432480
Am J Obstet Gynecol. 2000 Jun;182(6):1506-19
pubmed: 10871473
Lancet. 1997 Jun 28;349(9069):1864-7
pubmed: 9217757
Gynecol Oncol. 2011 Aug;122(2):275-80
pubmed: 21570713
Gynecol Oncol. 2012 Jun;125(3):531-5
pubmed: 22366409
Gynecol Oncol. 1996 Aug;62(2):169-73
pubmed: 8751545
J Nucl Med. 2003 Aug;44(8):1232-7
pubmed: 12902412
J Nucl Med. 2018 Feb;59(2):210-215
pubmed: 28912145
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
Eur J Surg Oncol. 2013 Jan;39(1):81-6
pubmed: 23117018
N Engl J Med. 2014 Feb 13;370(7):599-609
pubmed: 24521106
Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5
pubmed: 10522715
AJR Am J Roentgenol. 2008 Jun;190(6):1652-8
pubmed: 18492920
J Nucl Med. 2012 Sep;53(9):1438-45
pubmed: 22872741
Gynecol Oncol. 2009 Aug;114(2):151-6
pubmed: 19457548
Melanoma Res. 2008 Oct;18(5):346-52
pubmed: 18781133
Gynecol Oncol. 2012 Dec;127(3):462-6
pubmed: 22943880
Gynecol Oncol. 2006 Nov;103(2):714-8
pubmed: 16740298
Gynecol Oncol. 2009 Aug;114(2):315-8
pubmed: 19481787
Cancer. 1960 Jan-Feb;13:77-8
pubmed: 13828575
J Clin Oncol. 2012 Nov 1;30(31):3786-91
pubmed: 22753905
Cancer. 1977 Feb;39(2):456-66
pubmed: 837331
Ann Surg Oncol. 2013 Feb;20(2):353-4
pubmed: 23054121
Int J Clin Oncol. 2014 Feb;19(1):198-203
pubmed: 23371310
World J Radiol. 2012 May 28;4(5):207-14
pubmed: 22761980
Gynecol Oncol. 2009 May;113(2):163-9
pubmed: 19232699
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178
Gynecol Oncol. 2011 Aug;122(2):251-4
pubmed: 21570109
Ann Surg Oncol. 2015 Jan;22(1):40-5
pubmed: 25069859